[Medlife]SR 1664|1338259-05-4
简介:SR1664是一种PPARγ拮抗剂。SR1664与PPARγ结合并有效抑制Cdk5介导的PPARγ磷酸化(IC50=80nm;Ki=28.67纳米[1][2]。中文名称:4‘-[(2,3-二甲基-5-[(1s)-1-(4-硝基苯基)乙基]氨基甲酰基}-1H-吲哚-1-基)甲基]联苯-2-羧酸
简介:SR1664是一种PPARγ拮抗剂。SR1664与PPARγ结合并有效抑制Cdk5介导的PPARγ磷酸化(IC50=80nm;Ki=28.67纳米[1][2]。
SR1664物理化学性质:
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 828.8±65.0 °C at 760 mmHg |
分子式 | C33H29N3O5 |
分子量 | 547.601 |
闪点 | 455.0±34.3 °C |
精确质量 | 547.210693 |
PSA | 120.64000 |
LogP | 6.75 |
蒸汽压 | 0.0±3.2 mmHg at 25°C |
折射率 | 1.648 |
储存条件 | 2-8°C |
SR1664详细介绍:
中文名称: | 4'-[(2,3-Dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-i ndol-1-yl)methyl]-2-biphenylcarboxylic acid |
英文名称: | SR 1664 |
英文别名: | 4'-[(2,3-Dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-i ndol-1-yl)methyl]-2-biphenylcarboxylic acid;2,3-epoxy-1-[(triisopropylsilyl)oxy]propane;(S)-4'-((2,3-dimethyl-5-(1-(4-nitrophenyl)ethylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid;CTK0A4935;(S)-triisopropyl(oxiran-2-ylmethoxy)silane;Silane, tris(1-methylethyl)[(2S)-oxiranylmethoxy]-;(S)-3-Triisopropylsilyloxy-1,2-epoxypropane;(S)-4'-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid;(2S)-2,3-Epoxy-1-(triisopropylsilyloxy)propane;(S)-2,3-epoxy-1-[(triisopropylsilyl)oxy]propane;SR 1664;(2S)-2,3-Epoxy-1-(t;4′-[[2,3-Dimethyl-5-[[[(1S)-1-(4-nitrophenyl)ethyl]amino]carbonyl]-1H-indol-1-yl]methyl]- [1,1′-Biphenyl]-2-carboxylic acid |
CAS号: | 1338259-05-4 |
分子式: | C33H29N3O5 |
分子量: | 547.60 |
详细描述 | 抑制Cdk5介导的PPARγ磷酸化,抗糖尿病药 |
SR1664参考文献:
[1]. Marciano DP, Kuruvilla DS, Boregowda SV, et al. Pharmacological repression of PPARγ promotes osteogenesis. Nat Commun. 2015;6:7443. Published 2015 Jun 12.
[2]. Choi JH, et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477(7365):477-481. Published 2011 Sep 4.
Medlife品牌是国内知名的小分子化合物品牌,致力于信号通路、抑制剂、激动剂等产品的研发及产品供应服务,同时还可提供重组蛋白、植提、寡核苷酸等系列的产品。
本文引用地址:https://www.canspec.cn/product/894302.html